Under new CEO, Novo ends heart failure partnership with Japanese biotechnews2025-09-30T15:33:01+00:00September 30th, 2025|Endpoints News|
Genmab CEO on his yearslong interest in Merusnews2025-09-29T17:00:00+00:00September 29th, 2025|Endpoints News|
Tourmaline attracted small bidding war before $1.4B sale to Novartisnews2025-09-29T14:32:55+00:00September 29th, 2025|Endpoints News|
Mental health platform Wysa acquires physical therapy startup Kinsnews2025-09-29T13:00:44+00:00September 29th, 2025|Endpoints News|
Genmab to buy Merus for $8B, with multibillion-dollar plans in head and neck cancernews2025-09-29T10:52:41+00:00September 29th, 2025|Endpoints News|
Get your CVR: Backloaded acquisitions come into focus following Metsera, 89bio dealsnews2025-09-26T13:30:47+00:00September 26th, 2025|Endpoints News|
Pfizer’s Metsera deal could spark more M&A for pharmas ‘tiptoeing into obesity’news2025-09-25T14:58:48+00:00September 25th, 2025|Endpoints News|
Pfizer goes full speed ahead on obesity with $4.9B acquisition of Metseranews2025-09-22T10:49:36+00:00September 22nd, 2025|Endpoints News|
Pfizer, Arvinas to sell rights to lead PROTAC one month after filing for FDA reviewnews2025-09-18T14:14:45+00:00September 18th, 2025|Endpoints News|
Shape Therapeutics strikes AAV capsid deal with VectorY worth up to $1.2Bnews2025-09-18T13:45:49+00:00September 18th, 2025|Endpoints News|
